Date of SOH Approval: 10 October 2022

Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of CoronaVac COVID-19 Vaccine for children 6 to 17 years old. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

Evidence summary:  CoronaVac COVID-19 Vaccine for children 6 to 17 years old

HTAC Recommendation Preview: